Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Benoit

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
International Journal of Antimicrobial Agents|October 12, 2020
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in SenegalOcéane Delandre, Sokhna M Daffe, Mathieu Gendrot, et al.
Oncoimmunology|January 18, 2021
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS studyFabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
International Journal of Antimicrobial Agents|October 12, 2020
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in SenegalOcéane Delandre, Sokhna M Daffe, Mathieu Gendrot, et al.
Oncoimmunology|January 18, 2021
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS studyFabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Pageof 6